Form 4: Bio-Rad Laboratories Director Acquires Restricted Stock Units and Stock Options

Director Jon Faiz Kayyem reports acquisition of restricted stock units and stock options in Bio-Rad Laboratories.

Summary

• Jon Faiz Kayyem, a director of Bio-Rad Laboratories, filed a Form 4 disclosing changes in beneficial ownership.
• On May 20, 2025, Kayyem acquired 68,621 restricted stock units (RSUs) and 42,010 stock options.
• The RSUs vest in three equal installments on June 30, September 30, and December 31, 2025, contingent on continued service.
• The stock options, with an exercise price of $0.2708, also vest in three equal installments on June 30, September 30, and December 31, 2025, contingent on continued service.
• The options expire on May 19, 2035.
• Kayyem also holds deferred RSUs, which will be issued upon separation from service.

Sentiment

Score: 6

Explanation: The sentiment is neutral as it reflects a standard insider transaction. The acquisition of equity can be seen as a positive sign, but it's a routine event.

Positives

• The acquisition of RSUs and stock options aligns the director's interests with those of the shareholders.
• The vesting schedule incentivizes continued service with the company.

Future Outlook

The vesting of RSUs and stock options is contingent upon the director's continued service with the company.

Industry Context

Form 4 filings are standard practice for reporting changes in beneficial ownership by company insiders, providing transparency to investors.

Stakeholder Impact

• The acquisition of equity by a director can be viewed positively by shareholders as it aligns management's interests with theirs.

Key Dates

Keywords

Form 4, restricted stock units, stock options, beneficial ownership, director, Bio-Rad Laboratories, BDSX, Kayyem